Diabetic Macular Edema Clinical Trial
— ALTIMETEROfficial title:
An Exploratory, Prospective, Multi-Center, Open-Label, Single-Arm, Interventional, Phase IIB Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Patients With Diabetic Macular Edema Treated With Faricimab (RO6867461) - ALTIMETER STUDY
Verified date | November 2023 |
Source | Hoffmann-La Roche |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an exploratory, prospective, multicenter, open-label, single-arm, interventional, Phase IIb study designed to explore the associations over time between clinical assessments, multimodal imaging assessments, aqueous humor (AH) biomarker patterns, and genetic polymorphisms in participants with diabetic macular edema (DME) who are treated with faricimab.
Status | Completed |
Enrollment | 99 |
Est. completion date | December 22, 2022 |
Est. primary completion date | December 22, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis of diabetes mellitus (Type 1 or Type 2), as defined by the World Health Organization (WHO) and/or American Diabetes Association - Hemoglobin A1c (HbA1c) =10% - Patients who are intravitreal (IVT) treatment-naïve in the study eye - Diabetic macular edema (DME) defined as macular thickening by spectral-domain optical coherence tomography (SD-OCT) involving the center of the macula. This inclusion criterion is to be assessed by the central reading center (CRC). - Decreased visual acuity (VA) attributable primarily to DME - Clear ocular media and adequate pupillary dilation to allow acquisition of good quality retinal images to confirm diagnosis Exclusion Criteria: - Currently untreated diabetes mellitus or previously untreated patients who initiated oral or injectable anti-diabetic medication within 3 months prior to Day 1 - Any known hypersensitivity to any of the components in the faricimab injection, dilating eye drops, or any of the anesthetics and antimicrobial preparations used by the patient during the study - Any major illness or major surgical procedure within 1 month before the Day 1. One re-screening for this criterion is permitted - History of other diseases, other non-diabetic metabolic dysfunction, physical examination finding, historical or current clinical laboratory finding giving reasonable suspicion of a condition that contraindicates the use of the faricimab or that might affect interpretation of the results of the study or renders the patient at high-risk for treatment complications, in the opinion of the Investigator - Active cancer within the past 12 months prior to Day 1 except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate cancer with a Gleason score of =6 and a stable prostate-specific antigen for >12 months - Stroke or myocardial infarction within 12 months prior to the Day 1. One re-screening for this criterion is permitted - Any febrile illness within 1 week prior to Day 1. One re-screening for this criterion is permitted - Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of faricimab - Renal failure requiring renal transplant, hemodialysis, or peritoneal dialysis within 6 months prior to Day 1 or anticipated to require hemodialysis or peritoneal dialysis at any time during the study - Any condition resulting in a compromised immune system that is likely to impact the aqueous humor (AH) inflammatory biomarkers. - Patients who are currently enrolled in or have participated in any other clinical study involving an investigational product or device, or in any other type of medical research, within 3 months or 5 half-lives prior to Day 1 and up to completion of the current study - Substance abuse occurring within 12 months prior to screening, in the Investigator's judgment - Use of systemic immunomodulatory treatments within 6 months or 5 half-lives prior to Day 1 - Use of any systemic corticosteroids (including inhaled corticosteroids from inhalers used regularly, e.g., pulmonary disease, asthma, or seasonal allergy) within 1 month prior to Day 1 - Any prior or concomitant systemic anti-VEGF treatment within 6 months or 5 half-lives prior to Day 1 - Use of systemic medications known to be toxic to the lens, retina or optic nerve used during the 6-month period or 5 half-lives prior to Day 1 or likely need to be used - Received a blood transfusion within 3 months prior to the screening visit - Received any treatment that leads to immunosuppression within 6 months or 5 half-lives prior to Day 1 Ocular Exclusion Criteria for Study Eye: - High-risk PDR. This exclusion criterion is to be assessed by the CRC - Any history of or ongoing rubeosis iridis - Any panretinal photocoagulation or macular laser photocoagulation treatment received in the study eye prior to the screening visit or expected to be received between the screening visit and Day 1 - Any history of treatment with anti-VEGF or any periocular or IVT corticosteroids in the study eye and no such treatment planned for the time between screening and Day 1 - Any treatment for dry eye disease in the last month prior to Day 1. Lubricating eye drops and ointments are permitted. - Any treatment with anti-inflammatory eye drops within 1 month prior to Day 1 - Any intraocular surgery within 3 months prior to Day 1 or any planned surgery during the study - Any glaucoma surgery/laser procedure involving the iris, trabecular meshwork, or ciliary body prior to the screening visit. Only iris surgery/laser might be allowed if they occurred more than 6 months prior to Day 1. - History of vitreoretinal surgery/pars plana vitrectomy, corneal transplant, or radiotherapy - Any active or suspected ocular or periocular infections on Day 1 - Any presence of active intraocular inflammation on Day 1 or any history of intraocular inflammation - Any history of idiopathic, infectious, or noninfectious uveitis - Any current or history of ocular disease other than DME that may confound assessment of the macula or affect central vision - Any current ocular condition or other causes of visual impairment for which, in the opinion of the Investigator, VA loss would not improve from resolution of macular edema Ocular Exclusion Criteria for Fellow Eye: - Patient is currently receiving treatment with brolucizumab or bevacizumab in the non-study eye and is unwilling to switch to a protocol allowed non-study eye treatment during the study - Any previous treatment with Iluvien® or Retisert® in the non-study eye - Non-functioning non-study eye |
Country | Name | City | State |
---|---|---|---|
Argentina | Centro Oftalmológico Dr. Charles S.A. | Capital Federal | |
Argentina | Oftalmos | Capital Federal | |
Canada | Vitreous Retina Macula Specialists of Toronto | Etobicoke | Ontario |
Canada | The Retina Centre of Ottawa | Ottawa | Ontario |
Germany | Universitätsklinikum Tübingen | Tübingen | |
Italy | Irccs Ospedale San Raffaele;U.O. Oculistica | Milano | Lombardia |
Italy | Ospedale San Giuseppe; U.O. Oculistica | Milano | Lombardia |
Poland | Wojskowy Instytut Medyczny - Panstwowy Instytut Badawczy | Warszawa | |
United Kingdom | Gloucestershire Hospitals NHS Foundation Trust | Gloucestershire | |
United Kingdom | Kings College Hospital | London | |
United Kingdom | Sunderland Eye Infirmary | Sunderland | |
United States | Retina Res Institute of Texas | Abilene | Texas |
United States | Austin Research Center for Retina | Austin | Texas |
United States | Northwestern Medical Group/Northwestern University | Chicago | Illinois |
United States | Charles Retina Institute | Germantown | Tennessee |
United States | Cumberland Valley Retina PC | Hagerstown | Maryland |
United States | Long Is. Vitreoretinal Consult | Hauppauge | New York |
United States | Raj K. Maturi, MD PC | Indianapolis | Indiana |
United States | Bascom Palmer Eye Institute | Naples | Florida |
United States | University Retina and Macula Associates, PC | Oak Forest | Illinois |
United States | The Retina Institute | Saint Louis | Missouri |
United States | Retina Consultants of Texas | The Woodlands | Texas |
United States | Strategic Clinical Research Group, LLC | Willow Park | Texas |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche |
United States, Argentina, Canada, Germany, Italy, Poland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants With a =2-Step Improvement From Baseline on the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye at Week 24 | The ETDRS DRSS score of each participant's study eye was assessed using ultra-wide field color fundus photography (UWF-CFP) taken by trained personnel at the study sites. Analysis of the fundus photographs was performed by the central reading center, and the percentage of participants with a =2-step improvement from baseline was summarized along with a two-sided 95% Clopper-Pearson exact confidence interval. Baseline was defined as the participant's last observation prior to initiation of study drug. | Baseline and Week 24 | |
Secondary | Adjusted Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) in the Study Eye at Week 24 | Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for visit, age (continuous), baseline BCVA (continuous), and region (US and Canada and the rest of the world). An unstructured covariance structure was used. In case of convergence issues with the model, an AR (1) covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. | From Baseline to Week 24 | |
Secondary | Adjusted Mean Change From Baseline in Central Subfield Thickness in the Study Eye at Week 24 | Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using Spectral Domain-Optical Coherence Tomography (SD-OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model was adjusted for visit, age (continuous), baseline CST (continuous), and region (US and Canada and the rest of the world). An unstructured covariance structure was used. In case of convergence issues with the model, an AR (1) covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. | From Baseline to Week 24 | |
Secondary | Median Time to First Absence of DME in the Study Eye During the Study | An event was defined as the first absence of diabetic macular edema (DME) in the study eye, defined as first time reaching central subfield thickness (CST; ILM-RPE) <305 microns, after baseline. Baseline was defined as the participant's last observation prior to initiation of study drug. The time to first absence of DME was a Kaplan-Meier estimate. The 95% confidence interval (CI) for the median was computed using the method of Brookmeyer and Crowley. Participants without an event and discontinued from treatment were censored at the last CST assessment. | From Baseline to Week 24 | |
Secondary | Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye at Week 24 | The absence of intraretinal fluid (IRF) in the study eye (defined as IRF absent or definite outside center subfield only) was assessed by the central reading center using Spectral Domain-Optical Coherence Tomography (SD-OCT). The percentage of participants with absence of IRF and a two-sided 95% Clopper-Pearson exact confidence interval are reported. | Week 24 | |
Secondary | Percentage of Participants With Absence of Subretinal Fluid in the Study Eye at Week 24 | The absence of subretinal fluid (SRF) in the study eye (defined as SRF absent or definite outside center subfield only) was assessed by the central reading center using Spectral Domain-Optical Coherence Tomography (SD-OCT). The percentage of participants with absence of SRF and a two-sided 95% Clopper-Pearson exact confidence interval are reported. | Week 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03953807 -
A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated
|
Phase 4 | |
Completed |
NCT03622580 -
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
|
Phase 3 | |
Recruiting |
NCT06262737 -
Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
|
||
Terminated |
NCT04611152 -
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
|
Phase 3 | |
Terminated |
NCT04603937 -
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
|
Phase 3 | |
Active, not recruiting |
NCT04108156 -
This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab
|
Phase 3 | |
Completed |
NCT02867735 -
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
|
Phase 1 | |
Withdrawn |
NCT03629210 -
Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema
|
Phase 2 | |
Withdrawn |
NCT02842541 -
Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema
|
Phase 1 | |
Completed |
NCT02221453 -
Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide
|
Phase 2 | |
Completed |
NCT02979665 -
Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema
|
||
Completed |
NCT02556723 -
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
|
N/A | |
Completed |
NCT02000102 -
Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab
|
N/A | |
Completed |
NCT02088229 -
Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema
|
N/A | |
Terminated |
NCT00779142 -
Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies
|
N/A | |
Completed |
NCT01171976 -
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT00989989 -
Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema
|
Phase 3 | |
Completed |
NCT00683176 -
Effect of Choline Fenofibrate (SLV348) on Macular Edema
|
Phase 2 | |
Terminated |
NCT00768040 -
Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema
|
Phase 2 | |
Completed |
NCT01259609 -
Changes in Ciliary Body Thickness in Patients With Diabetic Macular Edema After Vitrectomy
|
N/A |